4D Molecular Therapeutics, Inc.
FDMT
$25.34
-$0.30-1.17%
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 826.69% | 562.47% | 1,014.45% | -19.55% | -87.21% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 826.69% | 562.47% | 1,014.45% | -19.55% | -87.21% |
| Cost of Revenue | 23.15% | 20.99% | 21.36% | 18.13% | 22.51% |
| Gross Profit | -1.27% | 0.97% | 5.01% | -19.65% | -59.85% |
| SG&A Expenses | 18.73% | 10.88% | 8.13% | 4.37% | 6.46% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 21.90% | 18.05% | 17.47% | 13.95% | 17.52% |
| Operating Income | -6.29% | -2.58% | 1.08% | -14.88% | -39.72% |
| Income Before Tax | 4.81% | 6.19% | 8.81% | -9.46% | -35.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 4.81% | 6.19% | 8.81% | -9.46% | -35.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 4.81% | 6.19% | 8.81% | -9.46% | -35.19% |
| EBIT | -6.29% | -2.58% | 1.08% | -14.88% | -39.72% |
| EBITDA | -5.26% | -0.96% | 3.33% | -13.14% | -38.63% |
| EPS Basic | 28.25% | 20.38% | 17.20% | 1.42% | -23.09% |
| Normalized Basic EPS | 28.25% | 20.38% | 17.20% | 1.42% | -23.07% |
| EPS Diluted | 28.28% | 20.41% | 17.23% | 1.45% | -23.13% |
| Normalized Diluted EPS | 28.25% | 20.38% | 17.20% | 1.42% | -23.07% |
| Average Basic Shares Outstanding | 32.95% | 20.67% | 14.44% | 11.38% | 11.56% |
| Average Diluted Shares Outstanding | 32.95% | 20.67% | 14.44% | 11.38% | 11.56% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
